Active Biotech AB Interim report January - September 2015
LUND, Sweden, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Laquinimod
- The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
- The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington's disease, are proceeding as planned
Tasquinimod
- The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ISI
- Only commercial activities will be conducted from 2016
Financial summary
| MSEK | July - Sept. | Jan. - Sept. | Jan. - Dec. | |||||
| 2015 | 2014 | 2015 | 2014 | 2014 | ||||
| Net sales | 5.2 | 2.6 | 11.3 | 7.5 | 10.4 | |||
| Operating loss | -22.2 | -55.7 | -149.7 | -172.8 | -228.5 | |||
| Loss for the period | -23.4 | -56.6 | -152.7 | -174.5 | -231.5 | |||
| Loss per share, before and after dilution (SEK) | -0.26 | -0.76 | -1.70 | -2.33 | -3.02 | |||
| Cash and cash equivalents (at the end of the period) | 132.4 | 161.0 | 328.5 | |||||
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 |
Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 00 |
The report is also available at www.activebiotech.com.
Active Biotech AB Interim report January - September 2015 http://hugin.info/1002/R/1964749/717166.pdf
HUG#1964749
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
